211 related articles for article (PubMed ID: 11291095)
1. IUdR polymers for combined continuous low-dose rate and high-dose rate sensitization of experimental human malignant gliomas.
Yuan X; Dillehay LE; Williams JR; Shastri VR; Williams JA
Int J Cancer; 2001 Apr; 96(2):118-25. PubMed ID: 11291095
[TBL] [Abstract][Full Text] [Related]
2. Synthetic, implantable polymers for IUdR radiosensitization of experimental human malignant glioma.
Yuan X; Dillehay LE; Williams JR; Williams JA
Cancer Biother Radiopharm; 1999 Jun; 14(3):187-202. PubMed ID: 10850303
[TBL] [Abstract][Full Text] [Related]
3. Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma.
Williams JA; Dillehay LE; Tabassi K; Sipos E; Fahlman C; Brem H
J Neurooncol; 1997 May; 32(3):181-92. PubMed ID: 9049879
[TBL] [Abstract][Full Text] [Related]
4. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.
Yuan X; Tabassi K; Williams JA
Radiat Oncol Investig; 1999; 7(4):218-30. PubMed ID: 10492162
[TBL] [Abstract][Full Text] [Related]
5. Protracted exposure radiosensitization of experimental human malignant glioma.
Williams JA; Williams JR; Yuan X; Dillehay LE
Radiat Oncol Investig; 1998; 6(6):255-63. PubMed ID: 9885941
[TBL] [Abstract][Full Text] [Related]
6. Synthetic, implantable polymers for local delivery of IUdR to experimental human malignant glioma.
Williams JA; Yuan X; Dillehay LE; Shastri VR; Brem H; Williams JR
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):631-9. PubMed ID: 9806525
[TBL] [Abstract][Full Text] [Related]
7. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts.
Ning S; Trisler K; Wessels BW; Knox SJ
Cancer; 1997 Dec; 80(12 Suppl):2519-28. PubMed ID: 9406705
[TBL] [Abstract][Full Text] [Related]
8. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain.
Brem H; Tamargo RJ; Olivi A; Pinn M; Weingart JD; Wharam M; Epstein JI
J Neurosurg; 1994 Feb; 80(2):283-90. PubMed ID: 8283268
[TBL] [Abstract][Full Text] [Related]
9. Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine.
Doiron A; Yapp DT; Olivares M; Zhu JX; Lehnert S
Cancer Res; 1999 Aug; 59(15):3677-81. PubMed ID: 10446981
[TBL] [Abstract][Full Text] [Related]
10. Effect of subsequent acute-dose irradiation on cell survival in vitro following low dose-rate exposures.
Mitchell CR; Joiner MC
Int J Radiat Biol; 2002 Nov; 78(11):981-90. PubMed ID: 12456285
[TBL] [Abstract][Full Text] [Related]
11. Equivalence of hyperfractionated and continuous brachytherapy in a rat tumor model and remarkable effectiveness when preceded by external irradiation.
Veninga T; Visser AG; van den Berg AP; van Hooije CM; van Geel CA; Levendag PC
Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1351-60. PubMed ID: 11286843
[TBL] [Abstract][Full Text] [Related]
12. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine radiosensitization in U251 human glioblastoma xenografts.
Kinsella TJ; Vielhuber KA; Kunugi KA; Schupp J; Davis TW; Sands H
Clin Cancer Res; 2000 Apr; 6(4):1468-75. PubMed ID: 10778979
[TBL] [Abstract][Full Text] [Related]
13. High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence--the University of Wisconsin experience.
Petereit DG; Sarkaria JN; Potter DM; Schink JC
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1267-74. PubMed ID: 10613322
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine-mediated radiosensitization in mouse and human tissues.
Kinsella TJ; Kunugi KA; Vielhuber KA; Potter DM; Fitzsimmons ME; Collins JM
Clin Cancer Res; 1998 Jan; 4(1):99-109. PubMed ID: 9516958
[TBL] [Abstract][Full Text] [Related]
15. Overview of radiosensitivity of human tumor cells to low-dose-rate irradiation.
Williams JR; Zhang Y; Zhou H; Gridley DS; Koch CJ; Slater JM; Little JB
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):909-17. PubMed ID: 19014780
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.
Petersen C; Petersen S; Milas L; Lang FF; Tofilon PJ
Clin Cancer Res; 2000 Jun; 6(6):2513-20. PubMed ID: 10873107
[TBL] [Abstract][Full Text] [Related]
17. Synthetic, implantable, biodegradable polymers for controlled release of radiosensitizers.
Yuan X; Fahlman C; Tabassi K; Williams JA
Cancer Biother Radiopharm; 1999 Jun; 14(3):177-86. PubMed ID: 10850302
[TBL] [Abstract][Full Text] [Related]
18. Local delivery of a synthetic endostatin fragment for the treatment of experimental gliomas.
Pradilla G; Legnani FG; Petrangolini G; Francescato P; Chillemi F; Tyler BM; Gaini SM; Brem H; Olivi A; DiMeco F
Neurosurgery; 2005 Nov; 57(5):1032-40; discussion 1032-40. PubMed ID: 16284573
[TBL] [Abstract][Full Text] [Related]
19. Influence of dose-rate, post-irradiation incubation time and growth factors on interphase cell death by apoptosis and clonogenic survival of human peripheral lymphocytes.
Meijer AE; Saeidi AB; Zelenskaya A; Czene S; Granath F; Harms-Ringdahl M
Int J Radiat Biol; 1999 Oct; 75(10):1265-73. PubMed ID: 10549603
[TBL] [Abstract][Full Text] [Related]
20. Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat.
Olivi A; Ewend MG; Utsuki T; Tyler B; Domb AJ; Brat DJ; Brem H
Cancer Chemother Pharmacol; 1996; 39(1-2):90-6. PubMed ID: 8995504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
